Media Citations

Our Reports

A wide portfolio of market research reports in the healthcare industry

latest reports

  • Stem Cell Therapy Contract Manufacturing Market, 2019-2030

    Stem Cell Therapy Contract Manufacturing Market, 2019-2030

    August 2019

    Advances in the fields of cell biology and regenerative medicine have led to the development of a variety of stem cell-based therapies for many cardiovascular, oncological, metabolic and musculoskeletal disorders. Driven by the revenues generated from stem cell therapies, the regenerative medicine market is anticipated to generate revenues worth USD 100 billion by 2030. With a promising pipeline of over 200 stem cell therapy candidates, it has become essential for developers to scale up the production of such therapeutic interventions.  Given that stem cell therapy manufacturing requires highly regulated, state-of-the-art technologies, it is difficult for stakeholders to establish in-house expertise for large-scale manufacturing of stem cell therapies. As a result, stem cell therapy developers have begun outsourcing their manufacturing operations to contract manufacturing organizations (CMOs) . Specifically, small and mid-sized players in this sector tend to outsource a substantial proportion of clinical and commercial-scale manufacturing processes to contract service providers. In addition, even big pharma players, with established in-house capabilities, are gradually entering into long-term business relationships with CMOs in order to optimize resource utilization and manage costs. According to a recent Nice Insight CDMO survey, about 55% of 700 respondents claimed to have collaborated with a contract service provider for clinical and commercial-scale product development requirements. Considering the prevalent trends, we believe that the stem cell therapy manufacturing market is poised to grow at a steady pace, driven by a robust pipeline of therapy candidates and technological advances aimed at mitigating challenges posed by conventional methods of production. Amidst tough competition, the availability of cutting-edge tools and technologies has emerged as a differentiating factor and is likely to grant a competitive advantage to certain CMOs over other players in the industry. Scope of the Report The “Stem Cell Therapies Contract Manufacturing Market, 2019 – 2030” report features an extensive study on contract service providers engaged in the development and manufacturing of stem cell therapies. The study features in-depth analyses, highlighting the capabilities of various stem cell therapy CMOs. Amongst other elements, the report includes: A detailed review of the contract manufacturing landscape for stem cell therapies, featuring a comprehensive list of active CMOs and analysis based on a number of parameters, such as year of establishment, company size, geographical location, number of stem cell therapy manufacturing facilities, source of stem cells (allogenic and autologous), types of services offered (culture development, stem cell identification / validation, stem cell banking, cryopreservation, logistics, fill / finish and regulatory filings), scale of operation (preclinical, clinical and commercial), types of stem cells (adult, embryonic and induced pluripotent) and therapeutic area (oncology and non-oncology).  An elaborate discussion of the various guidelines laid down by regulatory bodies related to stem cells and other cell-based therapies across various geographies, such as the North America (primarily the US), Europe and other regions. Elaborate profiles of the key players based in North America, Europe and Asia-Pacific that have a diverse range of capabilities for the development, manufacturing and packaging of stem cell therapies. Each profile includes an overview of the company, its financial performance (if available), information on service portfolio, stem cell therapy manufacturing facilities, and details on partnerships, recent developments and an informed future outlook.  An analysis of the recent collaborations (signed since 2015) focused on the contract manufacturing of stem cell therapies, based on various parameters, such as year of agreement, type of agreement, scale of operation, source of stem cells used, types of stem cells and location of companies entering the partnership. An informed estimate of the annual demand for stem cell therapies in terms of area (in square feet) dedicated to stem-cell related operations, based on various parameters, such as target patient population, price of the therapy, dosing frequency and dose strength. A detailed capacity analysis, taking into consideration the manufacturing capacities of various stakeholders (small-sized, mid-sized and large CMOs) in the market, based on data gathered via secondary and primary research. It also provides the distribution of global stem cell therapy manufacturing capacity by company size (small-sized, mid-sized and large), and geography (North America, Europe and Asia-Pacific) and scale of operation (preclinical / clinical and commercial). A detailed analysis to understand the relationship between the demand and supply in this field, comparing the presence of stem cell therapy developers and the availability / capability of contract manufacturers across different geographies. An analysis to identify the key performance indicators for service providers active in the domain, based on the information gathered via secondary research and primary research. One of the key objectives of the report was to estimate the future size of the market. Based on parameters, such as increase in number of clinical studies, target patient population, anticipated adoption of stem cell therapies and expected variation in manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the mid to long term, for the period 2019-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] source of stem cells (autologous and allogenic), [B] types of stem cells (adult, embryonic and induced pluripotent), [C] size of contract service provider company (small-sized, mid-sized and large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America, Europe and Asia and rest of the world). To account for the uncertainties associated with the manufacturing of stem cell therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.  The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders: Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing) David Mckenna, Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota Fiona Bellot, Business Development Manager, Roslin Cell Therapies   Gilles Devillers, General Manager, Bio Elpida Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi) All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.  

    ...read more
  • Antibody Drug Conjugates Market (5th Edition), 2019-2030

    Antibody Drug Conjugates Market (5th Edition), 2019-2030

    August 2019

    With six approved and marketed drugs, namely POLIVY™ (2019), LUMOXITI™ (2018), BESPONSA® (2017), MYLOTARG™ (2017, reapproval), KADCYLA® (2013) and ADCETRIS® (2011), antibody drug conjugates (ADCs) have become recognized as a potent class of targeted therapeutic agents catering to oncology and hematological diseases markets. The success of such conjugated products can be attributed to their ability to effectively identify and eliminate disease associated cells / pathogens, while limiting off target toxicities. Presently, ADCs are considered a part of mainstream healthcare regimens, having generated significant enthusiasm within the medical science community across the world.  The growing popularity and therapeutic potential of ADCs can also be correlated with an exponential increase in the number of patents that have been filed / granted; the cumulative patent count has increased from 1,395 in 2009 to over 16,500 in the first half of 2019. With more than 200 ADCs in clinical / preclinical stages of development, the industry is gradually shifting from relying on conventional technologies to newer and more robust approaches to conjugate such complex biomolecules. Over the years, a number of well-funded start-ups / small companies, offering novel conjugation technologies, more potent warheads and advanced linker technologies, have been established. In fact, multiple licensing agreements / collaborations have been inked in the past few years between drug developers and technology providers to advance the development of pipeline ADC candidates.   Using ADCs in combination with other drug / therapy classes is an emerging concept and multiple companies are evaluating their proprietary ADC candidates in combination with other established therapeutic classes, such as immune checkpoint inhibitors, epigenetic modulators and monoclonal antibodies. In addition, several other companies have introduced certain novel types of conjugated drug molecules; example of such companies include Bicycle Therapeutics (bicycle drug conjugate), BlinkBio (tunable drug conjugates), Cellectar Biosciences (phospholipid drug conjugate), Centrose (extracellular drug conjugate), Esperance Pharmaceuticals (peptide conjugate) and Nordic Nanovector (radionucleotide conjugate). We expect the ADC therapeutics market to growth at a healthy rate in the mid to long-term, driven by the introduction of new combination therapies involving ADCs, innovative ADC development and conjugation technologies, applications beyond oncology and the expansion of existing marketing authorizations to newer geographies across the world. Scope of the Report The ‘Antibody Drug Conjugates Market (5th Edition), 2019-2030’ report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: A detailed assessment of the current market landscape of ADCs, providing information on drug developer(s) and technology provider(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target antigen, type of linker, type of payload / warhead / cytotoxin, type of antibody, antibody origin, antibody isotype, type of therapy (monotherapy and combination therapy), combination drug (if being evaluated as combination therapy), target indication(s), line of treatment, route of administration and dosing frequency. Elaborate profiles of the clinical stage companies (shortlisted based on phase of development of the lead drug) and their respective product portfolios; each profile features an overview of the company, its financial information (if available), detailed information on advanced stage pipeline candidates (featuring a drug overview, clinical development plan and key clinical trial results) and an informed future outlook. An analysis of the most commonly targeted therapeutic indications and details of ADC candidates being developed against them, highlighting key epidemiological facts about the diseases and currently available treatment options, other than ADCs. A list of key opinion leaders (KOLs) within this domain, featuring detailed 2X2 matrices to assess the relative experience of key individuals, who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field. It also includes a schematic world map representation, highlighting the geographical locations of eminent scientists / researchers engaged in this domain. In addition, it presents an analysis assessing the credibility and (relative) level of expertise of different KOLs, based on number of publications, number of citations, number of clinical trials, number of affiliations and strength of professional network (based on information available on LinkedIn). An insightful competitiveness analysis of biological targets, featuring a [A] three-dimensional bubble representation that highlights the targets that are being evaluated for ADC development, taking into consideration the number of lead molecules based on a particular target, phase of development of candidate therapies, number of clinical trials and number of target disease indications, and [B] a five-dimensional spider-web analysis, highlighting the most popular biological targets based on a number of relevant parameters, including affiliated publications, grants received to support research on a particular target, number of industry players involved in drug development efforts based on a singular target and geographical distribution of associated clinical trials.  An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, licensing agreements (specific to technology platforms and product candidates), product development and commercialization agreements, clinical trial agreements, manufacturing agreements, mergers and acquisitions, manufacturing and service agreements, and other relevant agreements.  An analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are focused on developing ADCs. An in-depth analysis of the various patents that have been filed / granted related to ADCs till May 2019. It includes information on key parameters, such as patent type, publication year, geographical location, issuing authority, assigned CPC symbol, emerging focus areas and leading industry / academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis. A study of the various grants that have been awarded to research institutes engaged in projects related to ADCs, between 2011 and 2019 (till April), highlighting various important parameters, such as year of award, support period, amount awarded, funding institute, grant type, focus area, type of recipient organization, key project leaders, key regions and leading recipient organizations. An elaborate discussion on the various strategies that can be adopted by the drug developers across key commercialization stages, namely prior to product launch, during / post launch, including a timeline representation of the key strategies adopted by drug developers for the commercialization of their proprietary products.  An analysis of the key promotional strategies that have been adopted by the developers of marketed products, namely POLIVY™, LUMOXITI™, BESPONSA®, MYLOTARG™, KADCYLA® and ADCETRIS®. An assessment of the various therapeutics that are being evaluated in combination with ADCs. The study also presents the likely evolution of these therapeutics across different indications.  A review of the evolution of ADC conjugation technologies, highlighting the various approaches that have been adopted across different generations; in addition, it presents a review of the existing competition between various conjugation approaches that are available / under development. An overview of the studies conducted to better analyze non-clinical data and support first-in-human (FIH) dose selection in ADCs. The study presents findings from various ADC studies in different animal models. It also includes an analysis of the different methods used in estimating FIH doses. In addition, it highlights the possible FIH starting doses and estimated dose escalations required to reach human maximum tolerated dose (MTD). An elaborate discussion on various factors that form the basis for the pricing of ADC products, featuring different models / approaches that pharmaceutical companies may choose to adopt while deciding the price of their respective lead therapy candidates that are likely to be marketed in the coming years. A case study on manufacturing of ADCs, highlighting the key challenges, and a list of contract service providers that are involved in this domain. A case study on companies offering companion diagnostics that can potentially be used to make treatment related decisions involving ADCs, providing information on the geographical location of key diagnostic developers, affiliated disease biomarkers, assay technique involved, target indication(s), the type of sample required (tumor tissue, blood, bone marrow and others) and the drug candidates for which a particular test was developed. One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for ADCs, over the coming decade. Based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have provided an informed estimate on the likely evolution of the market for the period 2019-2030. The report includes potential sales forecasts of ADCs that are currently marketed or are in late stages of development. Additionally, it provides forecasts of the overall ADCs market, wherein the current and upcoming opportunity is segmented across [A] type of payload (MMAE, DM4, camptothecin, DM1, MMAF and others), [B] type of linker (VC, Sulfo-SPDB, SMCC, VA, hydrazone linker and others), [C] target indications (breast cancer, lymphoma (HL, NHL, ALCL), leukemia (AML, ALL), urothelial cancer, lung cancer (NSCLC, SCLC), ovarian cancer and others), [D] target antigens (CD30, HER2, CD22, CD33 and others (HER4, TROP-2, EGFR, FOLR1, MSLN, CD142, CD79b, DLL3, CD37, Nectin – 4, LIV-1, c-MET, BCMA, CD25, CD19 and ENPP3)), [E] technology providers (Seattle Genetics, ImmunoGen, StemCentRx, Immunomedics and others), and [F] key geographies (North America, Europe and Asia Pacific). To account for the uncertainties associated with the development of these novel therapeutics and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution. The opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following individuals: Alan Burnett (Professor, School of Medicine, Cardiff University) Aldo Braca (President and Chief Executive Officer, BSP Pharmaceuticals) and Giorgio Salciarini (Technical Business Development Senior Manager, BSP Pharmaceuticals) Anthony DeBoer (Director, Business Development, Synaffix) Christian Bailly (Director of CDMO, Pierre Fabre) Christian Rohlff, (Chief Executive Officer and Founder, Oxford BioTherapeutics) Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma) John Burt (Chief Executive Officer, Abzena) Jennifer L. Mitcham (Director,  SMARTag ADCs and Bioconjugates, Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions) Laurent Ducry (Head of Bioconjugates Commercial Development, Lonza) Mark Wright (Site Head, Piramal Healthcare) Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia) Tatsuya Okuzumi (Associate General Manager, Ajinomoto Bio-Pharma Services) Toshimitsu Uenaka (Executive Director, Eisai) and Takashi Owa (Chief Innovation Officer, Eisai) Wouter Verhoeven (Chief Business Officer, NBE-Therapeutics) Anonymous (Director, Business Development, Leading CMO) Anonymous (Chief Executive Officer, Leading CMO) All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

    ...read more
  • CAR-T Therapies Market (2nd Edition), 2019-2030

    CAR-T Therapies Market (2nd Edition), 2019-2030

    August 2019

    CAR-T cell therapies are based on the principle of harnessing the innate potential of the immune system to selectively target and destroy diseased cells. Encouraging clinical results reported across several completed and ongoing trials, coupled to lucrative financing, have inspired many biopharmaceutical developers and academic research groups to focus their efforts on this relatively novel class of cell-based immunotherapies. With two approved products, namely KYMRIAH® (Novartis) and YESCARTA® (Gilead Sciences), CAR-T cell therapies are presently considered among the most promising anticancer therapeutics available, with potential applications in treating other diseases as well. It is worth highlighting that 66% of the pipeline therapies are presently in the clinical stage.  Over 100 companies and 85 academic / research institutes are actively involved therapy development initiatives in this domain. The ongoing research activity in this domain has led to the discovery of several novel molecular targets, which can be exploited for cell therapy development. Further research and characterization of these targets has significantly strengthened the pipelines of stakeholder entities engaged in this market. Driven by the availability of innovative technology platforms, the CAR-T therapies market is poised for success in the long-run as several therapeutic leads have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.   Scope of the Report The “CAR-T Therapies Market, 2019-2030 (2nd edition)” report features an extensive study of the current market landscape and the future potential of CAR-T cell therapies. The report highlights the efforts of both industry players and academic organizations working in this domain. Amongst other elements, the report features the following: An analysis of the prevalent and emerging trends in this domain, as represented on the social media platform, Twitter, highlighting the yearly trend of tweets, most frequently talked about product candidates, popular disease indications, target antigens, and prolific authors and social media influencers. A detailed assessment of the current market landscape of CAR-T cell therapies with respect to type of developer (industry / non-industry), phase of development, target therapeutic indication(s), key target antigen(s), source of T-cells (autologous / allogenic), route of administration, type of therapy (monotherapy / combination therapy) and patient segment (children / adults / seniors). Comprehensive profiles of marketed and mid to late stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan and key clinical trial results. An analysis of the CAR constructs of clinical-stage CAR-T therapies based on the generation of CAR-T therapy (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of vector and type of co-stimulatory domain used. A detailed analysis highlighting several key opinion leaders (KOLs) in this domain. It features a 2X2 analysis to assess the relative experience of certain KOLs, who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field, and a schematic world map representation, indicating the geographical locations of eminent scientists / researchers involved in the development of CAR-T cell therapies. An analysis of the various CAR-T cell therapy focused clinical trials registered across the world, between 2009 and 2019, highlighting the year wise trend of initiation of such studies and distribution across different geographies. In addition, we have provided a detailed list of factors that have influenced the growth of CAR-T therapies, especially in China. An overview of the various focus therapeutic areas of therapy developers, including an assessment of the opportunity offered by oncological and non-oncological disease indications. A detailed discussion on innovative technology platforms that are being used for the development of CAR-T cell therapies, along with profiles of key technology providers. Further, it includes a relative competitiveness analysis of different CAR-T cell therapy-based gene editing platforms, based on various parameters, such as ease of system design, cost of technology, level of toxicity and efficiency of technology. A case study on manufacturing cell therapy products, highlighting the key challenges, and a list of contract service providers and in-house manufacturers that are involved in this space. An elaborate discussion on various factors that form the basis for pricing of cell therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a CAR-T cell therapy that is likely to be marketed in the coming years.  A review of the key promotional strategies that have been adopted by the developers of the marketed CAR-T cell therapies, namely KYMRIAH® and YESCARTA®.  One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for CAR-T cell therapies over the coming decade. Based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such therapies, we have provided an informed estimate on the likely evolution of the market over the period 2019-2030. The report includes potential sales forecasts of CAR-T cell therapies that are currently marketed or are in late stages of development. Additionally, it provides forecasts for the overall CAR-T cell therapy market, wherein both the current and upcoming opportunity is segmented across [A] target indications (acute lymphoblastic leukemia, non-Hodgkin’s lymphoma, multiple myeloma, chronic lymphocytic leukemia, hepatocellular carcinoma and colorectal cancer), [B] important target antigens (CD19, BCMA, GPC3 and EGFR) and [C] key geographical regions (North America, Europe and Asia Pacific). To account for the uncertainties associated with the development of these novel therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution. The opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company names): Tim Oldham (Chief Executive Officer, Cell Therapies) Vincent Brichard (Vice President, Immuno-Oncology, Celyad) Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital) Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics) Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies) Adrian Bot (Vice President, Scientific Affairs, Kite Pharma) Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys) Miguel Forte (Chief Operating Officer, TxCell) Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado) Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing) All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

    ...read more

trending reports

press releases

  • The contract manufacturing services market for stem cells is expected to be worth over USD 2.5 billion by 2030, claims Roots Analysis

    August 2019

    Driven by a robust and growing pipeline of stem cell therapies, the demand for development and manufacturing services for such advanced product candidates is anticipated to increase beyond the capabilities of innovator companies alone Roots Analysis has announced the addition of the “Stem Cell Contract Manufacturing Market, 2019-2030” report to its list of offerings.  Owing to a highly regulated production environment and the need for state-of-the-art technologies and equipment, it is difficult for innovators to establish in-house expertise for the large-scale manufacturing of stem cell therapies. As a result, stem cell therapy developers are increasingly relying on contract manufacturing organizations (CMOs) for their product development and manufacturing needs.  To order this 300+ page report, which features 120+ figures and 145+ tables, please visit this link  Key Market Insights  Over 80 CMOs presently claim to provide manufacturing services for stem cells therapies The market landscape is fragmented, featuring a mix of companies of all sizes; however, small and mid-sized companies represent 70% of the overall number of industry stakeholders. It is worth highlighting that over 50% of the CMOs claim to be capable of accommodating both clinical and commercial scales of operation. 100+ strategic alliances have been inked since 2015 In fact, nearly 60% of the abovementioned deals were established post 2016. Majority of these agreements were observed to be focused on the manufacturing of various types of stem cells. It is worth highlighting that the maximum number of partnerships related to stem cell therapies were reported in 2018. More than 80,000+ patients were reported to have been enrolled in stem cell therapy related trials, since 2010 As a result, the manufacturing demand for such therapies can be anticipated to grow significantly over the next decade. The report features detailed projections of the future clinical and commercial demand for stem cell manufacturing, based on parameters, such as target patient population, dosing frequency, dose strength, source of stem cells, type of stem cells and key geographies. Currently, there are more than 100 facilities dedicated to stem cell manufacturing  The maximum share of the installed capacity belongs to large (more than 1,000 employees) and very large (more than 5,000 employees) companies. The report provides a detailed capacity analysis, taking into consideration the reported manufacturing capacities of industry stakeholders, and offering estimates on the distribution of the global contract manufacturing capacity for stem cell therapies, by company size, scale of operation and geography.  By 2030, North America and Europe are anticipated to capture over 70% of the market share Overall, the market is anticipated to witness an annualized growth rate of more than 20% over the next decade. In the long-term, the opportunity is expected to be well distributed across key stakeholder companies, which offer services for a diverse range of allogenic and autologous stem cell therapies. To request a sample copy / brochure of this report, please visit this link     Key Questions Answered Who are the leading CMOs with expertise in stem cell production? What is the annual clinical and commercial demand for stem cell therapies? What is the current installed manufacturing capacity for stem cell therapies? What are the key challenges faced by stem cell manufacturers? What kind of partnership models (manufacturing agreements, licensing, process development, product development & commercialization, acquisitions, and others) are commonly adopted by stakeholders in this industry?  Which type of stem cells are anticipated to be responsible for generating the maximum revenues in this domain?  What fraction of stem cell manufacturing operations are presently outsourced to CMOs? How is the current and future market opportunity likely to be distributed across key market segments?     The USD 2.5 billion (by 2030) financial opportunity within the stem cells contract manufacturing market has been analyzed across the following segments: Scale of Operation Preclinical  Clinical Commercial Size of Contract Manufacturer  Small-sized Mid-sized Large / Very Large Source of Stem Cells Autologous Allogenic Type of Stem Cells Adult Embryonic Induced Pluripotent  Key geographical regions  North America (US) Europe (UK, France, Germany, Italy and Spain) Asia (Japan) Rest of the World The report features inputs from eminent industry stakeholders, according to whom the contract manufacturing opportunity related to stem cell therapies can be expected to witness substantial growth due to the rising demand for regenerative medicine across a number of therapeutic areas. The report includes detailed transcripts of discussions held with the following experts: Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing) David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota) Fiona Bellot (Business Development Manager, Roslin Cell Therapies)   Gilles Devillers (General Manager, Bio Elpida) Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi) The research covers detailed profiles of key players (illustrative list provided below) from across key global markets (North America, Europe and Asia-Pacific); each profile provides an overview of the company, information on its service portfolio, manufacturing facilities, financial performance (if available), details on recent developments, as well as an informed future outlook.  BioNTech Innovative Manufacturing Services Cell and Gene Therapy Catapult FUJIFILM Cellular Dynamics GenCure Lonza MEDINET Nikon CeLL innovation Progenitor Cell Therapy (PCT) Roslin Cells WuXi Advanced Therapeutics For additional details, please visit https://www.rootsanalysis.com/reports/view_document/stem-cell-therapy-contract-manufacturing-market-2019-2030/271.html or email sales@rootsanalysis.com You may also be interested in the following titles:  Global Stem Cell Therapy Market: Focus on Cardiovascular and Metabolic Disorders, 2019-2030 Vaccine Contract Manufacturing Market (2nd-edition), 2019-2030 Biopharma Contract Manufacturing Market (3rd Edition), 2019 - 2030 Contact: Gaurav Chaudhary +1 (415) 800 3415 +44 (122) 391 1091 Gaurav.Chaudhary@rootsanalysis.com

    ...read more
  • The antibody drug conjugates market is projected to be worth more than USD 15 Billion by 2030, growing at a CAGR of over 20%, claims Roots Analysis

    August 2019

    The growing popularity and therapeutic potential of antibody drug conjugates (ADCs) is evident in the rapid growth in intellectual capital, financing and partnership activity reported in the past five years Roots Analysis has announced the addition of “Antibody Drug Conjugates Market (5th Edition), 2019-2030” report to its list of offerings.  With six marketed drugs, ADCs are presently recognized as a potent class of targeted anticancer therapies, with the potential to be used to treat a variety of other disease indications. The success of such products can be attributed to their ability to effectively identify and eliminate disease associated cells / pathogens, with substantially lower risk of treatment related side effects.  To order this 600+ page report, which features 190+ figures and 280+ tables, please visit this link  Key Market Insights  Around 250 ADCs are currently under development   Of these, nearly 40% are in the clinical phase of development, while the rest are in the preclinical / discovery stage. Presently, most of such therapeutic leads are being developed against the HER2 antigen; other popular biological targets include CD30 and EGFR. 60% of clinical stage therapy candidates are designed for the treatment of solid tumors Within this segment, breast cancer (which represents a share of 22%) is currently the most popular target indication (in terms of number of therapy candidates in the pipeline), followed by non-small cell lung cancer (10%). ADC therapeutics are also being developed for hematological malignancies, such as multiple myeloma (31%), lymphoma (27%) and leukemia (27%). More than 11,000 patents have been filed / granted related to ADCs and affiliated technologies, since 2015 Around 40% of these intellectual property documents were filed / granted in the US; other key regions with significant intellectual capital include China, Japan, Canada, Korea and Taiwan. Leading non industry players (in terms of the size of intellectual property portfolio) include INSERM, University of California, Leland Stanford Junior University and University of Pennsylvania. USD 5+ billion has been invested by both private and public investors, till 2019 Around USD 2 billion was raised through venture capital financing alone, representing 40% of the total capital amount raised since 2011. Further, there have been six IPOs, from which companies claim to have raised over USD 1 billion in financing.  Partnership activity in this field has increased at an annualized rate of 30%     In fact, around 60% of the deals considered in this analysis were established post 2015, the maximum activity being reported in 2018. Majority of these agreements (over 100) were observed to be either R&D agreements and / or licensing deals. Over time, CMOs have become indispensable to the R&D and manufacturing activity in this domain Presently, 30 CMOs have the required capabilities to manufacture and conjugate ADCs; of these, 50% claim to be one-stop-shops, providing end-to-end services across all steps of ADC manufacturing. Further, over 80% of ADC contract manufacturers are based in either North America or Europe with facilities dedicated to ADC manufacturing / conjugation located in one or multiple regions. North America and Europe are anticipated to capture over 80% of the market share by 2030 It also worth noting that ADC products using VC linkers and SMCC linkers are likely to capture more than 60% of the market. Further, based on type of cytotoxic payload, ADCs using MMAE and DMI are anticipated to capture close to 50% of the overall market share. To request a sample copy / brochure of this report, please visit this link     Key Questions Answered Who are the leading industry and non-industry players engaged in this market?  Who are the key ADC development and manufacturing technology providers?  What are the prevalent and upcoming trends related to ADC payload and linkers? What are the new biologic target antigens being explored for ADC development? Who are the key / emerging CMOs, in different regions, that you can reach out to for your manufacturing requirements? Who are the key investors in the ADC market? What are the most prominent drugs / therapies being currently used in combination with ADCs? What kind of partnership models are commonly adopted by ADC developers / manufacturers?  Who are the key opinion leaders / experts who can support contemporary ADC development efforts? How is the current and future market opportunity likely to be distributed across key market segments? What kind of commercialization and promotional strategies are being used by ADC developers? The USD 15 billion (by 2030) financial opportunity within this market has been analyzed across the following segments: Type of Payload MMAE  DM4 Camptothecin DM1 MMAF  Others Type of Linker VC  Sulfo-SPDB SMCC  VA Hydrazone  Others Target Indication Breast cancer Lymphoma  Leukemia  Urothelial cancer Lung cancer  Ovarian cancer Others Target Antigen CD30 HER2 CD22 CD33 Others  Technology Providers Seattle Genetics  ImmunoGen  StemCentRx  Immunomedics  Others Key Geographical Regions  North America Europe Asia Pacific The report features inputs from eminent industry stakeholders, according to whom upcoming generations of ADC therapeutics are likely to garner significant interest among therapy developers and end users alike. The report includes detailed transcripts of discussions held with the following experts: Alan Burnett (Professor, School of Medicine, Cardiff University) Aldo Braca (President and Chief Executive Officer) and Giorgio Salciarini (Technical Business Development Senior Manager, BSP Pharmaceuticals) Anthony DeBoer (Director, Business Development, Synaffix) Christian Bailly (Director of CDMO, Pierre Fabre) Christian Rohlff, (Chief Executive Officer and Founder, Oxford BioTherapeutics) Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma) John Burt (Chief Executive Officer, Abzena) Jennifer L. Mitcham (Director, SMARTag ADCs and Bioconjugates) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions) Laurent Ducry (Head of Bioconjugates Commercial Development, Lonza) Mark Wright (Site Head, Piramal Healthcare) Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia) Tatsuya Okuzumi (Associate General Manager, Ajinomoto Bio-Pharma Services) Toshimitsu Uenaka (Executive Director) and Takashi Owa (Chief Innovation Officer, Eisai) Wouter Verhoeven (Chief Business Officer, NBE-Therapeutics) The research covers elaborate profiles, featuring an overview of the company, its financial information (if available), detailed information on advanced stage pipeline candidates (featuring a drug overview, clinical development plan and key clinical trial results) and an informed future outlook.  AbbVie Astellas Pharma AstraZeneca Daiichi Sankyo Pfizer Roche / Genentech Synthon Bayer HealthCare Biotest Pharmaceuticals For additional details, please visit https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html or email sales@rootsanalysis.com  You may also be interested in the following titles:  ADC Contract Manufacturing Market (3rd Edition), 2018-2030 Gene Therapy Market (3rd Edition), 2019 - 2030 Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030 Contact: Gaurav Chaudhary +1 (415) 800 3415 +44 (122) 391 1091 Gaurav.Chaudhary@rootsanalysis.com

    ...read more
  • The large volume wearable injectors market is anticipated to grow at a CAGR of 40%, claims Roots Analysis

    August 2019

    The shift to self-administration of medication, coupled to the need to improve therapy adherence, have driven device developers to design versatile drug delivery devices capable of minimizing dosing-related errors and preventing needlestick injuries Roots Analysis has announced the addition of “Large Volume Wearable Injectors Market (4th Edition), 2018-2030” report to its list of offerings.  Over time, both drug developers and medical device manufacturers, have entered into strategic alliances to combine their respective expertise and develop appropriate drug-device combination products. Presently, multiple such combinations, facilitating easy delivery of both insulin and non-insulin drugs, in large volumes, are either already available in the market or under development.  To order this 350+ page report, which features 105+ figures and 130+ tables, please visit this link  Key Market Insights  Close to 50 large volume wearable injectors are available / under development  Around 17% of such devices have been designed to hold 10-15 ml of drug formulation, while 23% claim to have the capacity to hold more than 15 ml. Concerning type of dosing, 40% of these devices are developed / being developed for bolus dosing, and 40% for continuous dosing, the remaining (20%) devices are capable of facilitating both types of doses.  At present, there are 80+ biologics / small molecules that are most likely to be developed as drug-device combination products  The report provides insights on over 600+ marketed drugs / therapies and pipeline candidates, assessing the likelihood of whether they may be developed in combination with large volume wearable injectors or not. The analysis takes into consideration stage of development, dosage, dose concentration, route of administration, type of dose and drug sales (in case of marketed drugs). Close to 2,000 patents pertaining to large volume wearable injectors have been filed / granted till 2018 Most of the intellectual property documents in this field were observed to be associated with personal health monitoring systems, electronic patient care, needle retraction systems and smartphone-based drug delivery systems and solutions.   Outsourcing has emerged as a popular strategy for manufacturing device-related components The development process of high-volume drug injection devices is complex, characterized by the need for multiple components (electrical and mechanical modules) and multidisciplinary technical experience. It is worth highlighting that close to 50% of the total number of CMOs involved in providing services for such injectors, are based in North America.  Several clinical trials, evaluating drug-device combinations, were initiated between 2016 and 2018 Close to 60% of such trials are presently in the early (Phase I and Phase II) stages. The report features an in-depth analysis of clinical research initiatives in this field based on relevant parameters, such as trial registration year, current trial status, phase of development, and study design. North America and Europe are anticipated to capture over 60% of the overall market share by 2030 Presently, only patch injectors are available in the market, therefore, they are the sole contributors to the current market size. However, by 2030, 19% of the overall market share is expected to be captured by infusion pumps. To request a sample copy / brochure of this report, please visit this link     Key Questions Answered How is the current and future market opportunity likely to be distributed across key market segments?  Who are the leading drug delivery device manufacturers in this market?  How do modern large volume, wearable injector devices compare to each other (in terms of key specifications and strengths of manufacturer companies)? What are the prevalent R&D trends related to large volume wearable injectors (in terms of clinical research activity, and number of patents)? What is the role of contract manufacturing organizations in the supply chain of large volume wearable injectors? What are the recent developments and enabling technologies that are likely to influence the future of the large volume wearable injectors market? The USD 650 million (by 2030) financial opportunity within the large volume wearable injectors market has been analyzed across the following segments: Type of device Patch Pumps / Injectors Infusion Pumps / Injectors Usability Disposable Reusable Therapeutic Area  Neurological Disorders Oncological Disorders Cardiovascular Disorders Pain Management Infectious Diseases Key geographical regions  North America Europe Asia-Pacific Rest of the World The report features inputs from eminent industry stakeholders, according to whom the market is likely to be driven drug-device combinations of biologics (with the appropriate delivery devices), which are generally required to be administered in large volumes. Moreover, developers are attempting to gain a competitive edge by including certain distinguishing features, such as integrated mobile applications with smart health monitoring, provisions for audiovisual notifications, automatic drug reconstitution and error alerts, in their proprietary products. The report includes detailed transcripts of discussions held with the following experts: Menachem Zucker (Vice President and Chief Scientist, Elcam Medical) Mike Hooven (President and Chief Executive Officer, Enable Injections) Mark Banister (Chief Executive Officer, Medipacs) Pieter Muntendam (President and Chief Executive Officer, scPharmaceuticals) Mindy Katz (Director of Product, Sorrel Medical) Jesper Roested (Chief Executive Officer, Subcuject) Graham Reynolds (Vice President & General Manager, Global Biologics, West Pharmaceutical Services) Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services) The research includes detailed profiles, featuring an overview of the company, its financial information (if available), and a description of the product(s) offered. Each company profile includes recent developments related to large volume wearable injectors and an informed opinion on the likely strategies that may be adopted by these players to fuel growth in the foreseen future.  Becton Dickinson Bespak Cellnovo CeQur Debiotech Eli Lilly Enable Injections Insulet Medtronic PharmaSens Roche SOOIL Development Sonceboz Sensile Medical SteadyMed Therapeutics Tandem Diabetes Care Weibel CDS West Pharmaceutical Services For additional details, please visit  https://www.rootsanalysis.com/reports/view_document/large-volume-wearable-injectors-market-4th-edition-2018-2030/238.html or email sales@rootsanalysis.com You may also be interested in the following titles:  Medical Device Contract Manufacturing Market, 2019-2030 Biologics Fill / Finish Services Market, 2019 – 2030 Medical Device CROs Market, 2018-2030 Contact: Gaurav Chaudhary +1 (415) 800 3415 +44 (122) 391 1091 Gaurav.Chaudhary@rootsanalysis.com

    ...read more

The Roots Analysis Edge

200 +

Reports

40 +

Major Pharma Markets

400 +

Clients

50 +

Analytical Frameworks

Consulting

Market insights from across the industry value chain tailored to meet your business needs

  • All
  • Drug Discovery
  • Research & Development
  • Commercialization
  • Affilated services
  • Pipeline Tracking

  • Therapy Area Assessment

  • Clinical Trial Tracking

  • KOL Selection

  • Publication Analysis

  • Investment Analysis

  • Market Assessment

  • Deal Tracking

  • Competitive Profiling

  • Commercial Strategy and Business Development

Why Choose Us?

We are your partners with no equity

We fit in your budget

We love what we do

chance to prove ourselves

Best in class quality of work

Most trusted consulting partner in the industry